Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 15 September

Sam Kanaan
September 15, 2023

Morning Bell 14 September

Grady Wulff
September 14, 2023

Morning Bell 13 September

Grady Wulff
September 13, 2023

Morning Bell 12 September

Sam Kanaan
September 12, 2023

Morning Bell 11 September

Grady Wulff
September 11, 2023

Weekly Wrap 8 September

Grady Wulff
September 8, 2023

Morning Bell 7 September

Sam Kanaan
September 7, 2023

Morning Bell 6 September

Grady Wulff
September 6, 2023

Morning Bell 5 September

Grady Wulff
September 5, 2023

Morning Bell 4 September

Grady Wulff
September 4, 2023

Weekly Wrap 1 September

Grady Wulff
September 1, 2023